Rhizen Pharmaceuticals S.A. announces poster presentations of RP7214, a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) in preclinical models of Acute Myeloid Leukemia (AML) at the 2019 AACR-NCI-EORTC Conference

La Chaux-de-Fonds, SWITZERLAND


La Chaux-de-Fonds, Switzerland, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations of RP7214, a novel small molecule inhibitor of DHODH in preclinical models of Acute Myeloid Leukemia (AML).

Highlights from the two posters include: 

  •  RP7214 is a potent and novel DHODH inhibitor in AML acting via suppression of cellular pyrimidine pools and promoting differentiation to fully mature cells
  •  RP7214 demonstrated single-agent activity in AML cell lines and anti-tumor activities in both tumor size and tumor weight in MV-4-11 human leukemia xenograft model
  •  RP7214 potentiated the activity of gilteritinib (XOSPATA) in reducing cell growth, induction of apoptosis, cell cycle arrest and inhibition of pAkt and pErk 1/2
  •  RP7214 demonstrated anti-tumor activities manifested by a reduction in both tumor size and tumor weight in MV-4-11 human leukemia xenograft model when combined with cytarabine (ARA-C)

About RP7214:

RP7214 is a novel oral small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) with demonstrated preclinical activity in myeloid malignancies and solid tumors.  The compound is currently being evaluated in IND-enabling tolerability studies with a Phase I clinical trial in Myeloid Malignancies expected to commence in 2020.

Details of the poster presentations:

-- Poster Title:  Inhibition of Dihydroorotate Dehydrogenase (DHODH) by RP7214 attenuates growth and promotes differentiation of AML cell lines

  •  Session Title:                          Therapeutic Agents: Other 
  •  Session Date:                         Tuesday, October 29, 2019
  •  Session Start Time:                12:30                                      
  •  Session End Time:                 16:00
  •  Location:                                 Hall D, Hynes Convention Center
  •  Permanent Abstract No.:        C042

-- Poster Title:  RP7214, a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), potentiates activity of Gilteritinib and Cytarabine in preclinical models of AML

  •  Session Title:                          Therapeutic Agents: Other 
  •  Session Date:                         Tuesday, October 29, 2019
  •  Session Start Time:                12:30                                      
  •  Session End Time:                 16:00
  •  Location:                                 Hall D, Hynes Convention Center
  •  Permanent Abstract No.:        C044

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders.  Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.  Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland.  For additional information, please visit Rhizen’s website, www.rhizen.com.

                    

        

Contact Data